Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)

IntroductionStatus epilepticus (SE) is a life-threatening neurological emergency. SE lasting longer than 120 min and not responding to first-line and second-line antiepileptic drugs is defined as ‘refractory’ (RCSE) and requires intensive care unit treatment. There is currently neither evidence nor...

Full description

Saved in:
Bibliographic Details
Published inBMJ open Vol. 6; no. 6; p. e011565
Main Authors Rosati, Anna, Ilvento, Lucrezia, L'Erario, Manuela, De Masi, Salvatore, Biggeri, Annibale, Fabbro, Giancarlo, Bianchi, Roberto, Stoppa, Francesca, Fusco, Lucia, Pulitanò, Silvia, Battaglia, Domenica, Pettenazzo, Andrea, Sartori, Stefano, Biban, Paolo, Fontana, Elena, Cesaroni, Elisabetta, Mora, Donatella, Costa, Paola, Meleleo, Rosanna, Vittorini, Roberta, Conio, Alessandra, Wolfler, Andrea, Mastrangelo, Massimo, Mondardini, Maria Cristina, Franzoni, Emilio, McGreevy, Kathleen S, Di Simone, Lorena, Pugi, Alessandra, Mirabile, Lorenzo, Vigevano, Federico, Guerrini, Renzo
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 15.06.2016
BMJ Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IntroductionStatus epilepticus (SE) is a life-threatening neurological emergency. SE lasting longer than 120 min and not responding to first-line and second-line antiepileptic drugs is defined as ‘refractory’ (RCSE) and requires intensive care unit treatment. There is currently neither evidence nor consensus to guide either the optimal choice of therapy or treatment goals for RCSE, which is generally treated with coma induction using conventional anaesthetics (high dose midazolam, thiopental and/or propofol). Increasing evidence indicates that ketamine (KE), a strong N-methyl-d-aspartate glutamate receptor antagonist, may be effective in treating RCSE. We hypothesised that intravenous KE is more efficacious and safer than conventional anaesthetics in treating RCSE.Methods and analysisA multicentre, randomised, controlled, open-label, non-profit, sequentially designed study will be conducted to assess the efficacy of KE compared with conventional anaesthetics in the treatment of RCSE in children. 10 Italian centres/hospitals are involved in enrolling 57 patients aged 1 month to 18 years with RCSE. Primary outcome is the resolution of SE up to 24 hours after withdrawal of therapy and is updated for each patient treated according to the sequential method.Ethics and disseminationThe study received ethical approval from the Tuscan Paediatric Ethics Committee (12/2015). The results of this study will be published in peer-reviewed journals and presented at international conferences.Trial registration numberNCT02431663; Pre-results.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2016-011565